pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,503 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1781Endpoints1387Fierce Biotech706BioSpace698BioPharma Dive524raps234onclive165fda recalls
therapy area
allOncology12303Rare Disease3214Immunology2862Cardiology2744Hematology2177Pulmonology2138Vaccines
  • Sequencing antibody-drug conjugates adds complexity to recurrent endometrial cancer treatment
    Therapy sequencing for recurrent endometrial cancer is becoming increasingly complex as immunotherapy moves earlier in the treatment pathway and antibody-drug conjugates (ADCs) gain traction. Expe…
    onclive · 6mo agoNeutral↗ source
  • Experts highlight need for broader monitoring in polycythemia vera as patient shows disease progression despite controlled hematocrit
    A 68-year‑old woman with a six‑year history of polycythemia vera (PV) and prior deep‑vein thrombosis has kept her hematocrit below 45% on hydroxyurea, indicating good control of that metric. Desp…
    onclive · 6mo agoNeutral↗ source
← prev
page 124 of 141
next →
113
fda medwatch111
globenewswire health73
fda press59
1794
Psychiatry & CNS1204
Ophthalmology1060
Pain777
Endocrinology & Metabolism776
Nephrology760
New sepsis AI models face adoption hurdles despite improved performance
Hospitals once embraced an Epic sepsis‑prediction algorithm that promised early alerts for a condition that kills over 350,000 Americans each year. In practice the tool generated far more alerts th…
STAT · 6mo agoNeutral↗ source
  • Patient groups seek Medicaid work requirement exemptions for HIV and sickle cell patients
    Patient groups are urging the federal government to exempt certain disease populations from a new Medicaid work requirement rule. The rule, added by a 2017 tax bill, would require beneficiaries to…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • AUA and SUO Issue 2026 Update to Advanced Prostate Cancer Guideline
    The American Urological Association (AUA) and the Society of Urologic Oncology (SUO) have released an amendment to their Advanced Prostate Cancer Guideline for 2026. The update revises recommendat…
    onclive · 6mo agoNeutral↗ source
  • Delayed and re-emergent immune-related adverse events can persist years after melanoma checkpoint therapy, says expert
    Dr. Michael A. Postow, chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, explained that immune checkpoint inhibitors (ICIs) for melanoma have a distinct toxicity profile comp…
    onclive · 6mo agoNeutral↗ source
  • GU oncology experts preview top abstracts slated for ASCO 2026
    The 2026 ASCO Annual Meeting will run from May 29 to June 2 in Chicago, featuring a dedicated genitourinary (GU) oncology program. Leading clinicians were asked what upcoming abstracts they conside…
    onclive · 6mo agoNeutral↗ source
  • Experts discuss emerging role of TROP2-directed ADCs in EGFR-mutated lung cancer
    The segment, part of a series on EGFR‑mutated non‑small cell lung cancer, featured Dr. Jacob Sands together with Drs. Heather Wakelee and Alissa Cooper. They explained that TROP2‑directed antibody…
    onclive · 6mo agoNeutral↗ source
  • Dr. Postow stresses need for long-term multidisciplinary monitoring after melanoma immunotherapy
    Dr. Michael Postow, chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, emphasizes the importance of long-term multidisciplinary monitoring for patients who have completed immu…
    onclive · 6mo agoNeutral↗ source
  • Men less likely to seek suicide help despite higher discussion rates, Crisis Text Line report shows
    The nonprofit Crisis Text Line reviewed 1.5 million text messages it received in 2025 and discovered that fewer than one‑fifth of the users identified as male only. Even though men made up a small…
    STAT · 6mo agoNegative↗ source
  • Experts discuss treatment sequencing after progression in multiple myeloma
    In a recent video segment, Dr. Ajay K. Nooka, Dr. Noopur S. Raje and Dr. Surbhi Sidana lead a discussion on how to approach treatment sequencing for patients whose multiple myeloma has progressed.…
    onclive · 6mo agoNeutral↗ source
  • Alcohol screening often skipped in primary care, raising health costs
    Doctors are expected to ask patients about their alcohol consumption during routine checkups, but many primary care visits omit or rush this conversation. Evidence-based screening tools can be app…
    STAT · 6mo agoNegative↗ source
  • STAT investigates why alcohol remains America’s leading cause of death and calls for Medicaid work requirement exemptions
    STAT’s D.C. Diagnosis newsletter examines why alcohol continues to be the United States' deadliest drug, highlighting its persistent impact on public health. The piece references cultural commenta…
    STAT · 6mo agoNegative↗ source
  • Journalist reflects on challenges of reporting healthcare AI after fellowship
    The author participated in a journalism fellowship that focused on health technology reporting. The experience underscored the importance of continuously examining the incentives that drive AI pro…
    Endpoints · 6mo agoNeutral↗ source
  • PCOS renamed PMOS after decade-long scientific effort
    A new name for the condition formerly known as polycystic ovary syndrome (PCOS) has been introduced. The term polyendocrine metabolic ovarian syndrome (PMOS) was presented in a paper published in…
    STAT · 6mo agoPositive↗ source
  • FDA approves brexu-cel CAR-T therapy for relapsed/refractory mantle cell lymphoma, highlighting safety considerations
    The U.S. Food and Drug Administration has granted approval to brexu-cel, a CAR T-cell therapy, for patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first CAR T indicatio…
    onclive · 6mo agoApprovalPositive↗ source
  • CSL shares plunge to nine-year low after cutting revenue forecast and announcing $5 billion impairment
    CSL's shares fell to their lowest level since early 2017 after the company reduced its full‑year revenue guidance by roughly four percent. The guidance cut signals slower sales growth than previous…
    Endpoints · 6mo agoEarningsNegative↗ source
  • Rezdiffra Beats Wall Street Forecasts as MASH Market Expands
    Rezdiffra, a drug candidate targeting metabolic dysfunction‑associated steatohepatitis (MASH), is outperforming analysts' expectations according to recent commentary. The optimism comes as the mar…
    Endpoints · 6mo agoPositive↗ source
  • Astellas revisits gene therapy for XLMTM, offering new hope after earlier setbacks
    A gene therapy for the rare muscle disorder X‑linked myotubular myopathy (XLMTM) showed mixed results in early trials, with some boys experiencing dramatic recoveries while others died. Astellas P…
    STAT · 6mo agoPositive↗ source
  • Dr. Silbermann highlights trial design priorities for multiple myeloma, from supportive care to diverse enrollment
    Dr. Rebecca Silbermann, an associate professor at Oregon Health & Science University, outlined key considerations for designing multiple myeloma clinical trials. She stressed the importance of alig…
    onclive · 6mo agoNeutral↗ source
  • Supreme Court pauses restrictions, keeps abortion pill mifepristone available through pharmacies and mail
    The Supreme Court issued an order that maintains current access to the abortion medication mifepristone while it reviews a case challenging FDA prescribing rules. The order, signed by Justice Samu…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Colombian court upholds compulsory license for HIV drug, affirming legal framework
    The Court of Justice of the Andean Community ruled that Colombia's issuance of a compulsory license for an HIV medicine two years ago was lawful. The tribunal said the government had a valid publi…
    STAT · 6mo agoRegulatoryPositive↗ source
  • Zanubrutinib shows longer overall survival than ibrutinib in real-world relapsed/refractory mantle cell lymphoma
    A retrospective real‑world analysis examined outcomes of covalent BTK inhibitors in patients with relapsed or refractory mantle cell lymphoma who received treatment in the second or third line. Th…
    onclive · 6mo agoPositive readoutPositive↗ source
  • Medicare falls short on projected Alzheimer’s drug costs as fewer seniors use Leqembi
    Bob Herman reports that Medicare's earlier estimate that the new Alzheimer's therapy Leqembi would cost the program $3.5 billion in 2025 has proved far too high. The agency's actuaries based the fo…
    STAT · 6mo agoRegulatoryNegative↗ source
  • FDA policy lets some flavored vapes stay on shelves without full approval, raising expert concerns
    The Food and Drug Administration announced a new guidance that allows certain flavored e-cigarettes and nicotine pouches to remain on the market even though they have not received full authorizatio…
    STAT · 6mo agoRegulatoryNegative↗ source